Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...

Indian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...

The most impactful AI products of 2026 aren't built to do everything; they're built to solve one problem exceptionally well. The ET Most In...

Markets saw a strong rebound on Friday, driven by positive global cues and easing geopolitical tensions. Nifty defended the 23,000 support ...

We are in a phase in the US-Israel-Iran war where statements are made, then retracted. And, in a matter of just 48 hours, they are made all...

There are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...

India is increasingly becoming a long-term structural investment destination rather than a short-term strategic bet. Global capital is movi...

he first wave of artificial intelligence was defined by models, capabilities, and technical breakthroughs. The next may be defined by somet...

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

Hyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic ...

The government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...

Meta has unveiled Meta Business Agent, an AI-powered assistant designed to help businesses automate customer support, sales, scheduling and...

Cancer patients in India are struggling to find essential platinum-based drugs. A surge in global platinum prices and supply chain issues a...

India's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...

India is ready to welcome high-quality global pharmaceutical products. This move is in exchange for better market access for Indian drug ex...

Viyash Scientific, backed by Carlyle, is acquiring Italy's BioForLife for Rs. 188 crore. This move aims to build a leading global companion...

Indian pharma exports to the US face a subdued outlook this year. Policy uncertainties, falling generic prices, and regional conflicts are ...